Mouse Model Startup Mirimus Sets Sights on Industry Customers | GenomeWeb

As its contract with the National Cancer Institute nears completion, startup Mirimus is hoping to begin adding drug companies to the list of customers for its inducible-RNAi mouse models, Mirimus CEO Prem Premsrirut said this week.

At this point, the majority of Mirimus' clients are academics, which have been easier to approach given Mirimus' status as a spinout of Cold Spring Harbor Laboratory, she told Gene Silencing News. “The commercial customers we're aiming for ... will take a little bit more time.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.